{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:35:16Z","timestamp":1792017316840,"version":"4.4.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1196225"],"award-info":[{"award-number":["1196225"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2009965"],"award-info":[{"award-number":["2009965"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1197190"],"award-info":[{"award-number":["1197190"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004752","name":"State Government of Victoria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004752","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001171","name":"Cancer Institute NSW","doi-asserted-by":"publisher","award":["TPG172146"],"award-info":[{"award-number":["TPG172146"]}],"id":[{"id":"10.13039\/501100001171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ebiom.2025.106058","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T10:34:47Z","timestamp":1765190087000},"page":"106058","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Characterising the effect of circulating sphingolipids on metastatic prostate cancer cells"],"prefix":"10.1016","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0248-0258","authenticated-orcid":false,"given":"Neil","family":"Portman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3068-2498","authenticated-orcid":false,"given":"Blossom","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ming","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel M.N.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhiannon","family":"Mellor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Ardolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Raneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahlia","family":"Scheinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Handelsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Moujaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Meikle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5159-4580","authenticated-orcid":false,"given":"Anthony M.","family":"Joshua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Hoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6842-9223","authenticated-orcid":false,"given":"Lisa G.","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ebiom.2025.106058_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.ebiom.2025.106058_bib2","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a033688","article-title":"Metastases in prostate cancer","volume":"9","author":"Manna","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"2","key":"10.1016\/j.ebiom.2025.106058_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15020461","article-title":"Metastatic prostate cancer-a review of current treatment options and promising new approaches","volume":"15","author":"Posdzich","year":"2023","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.ebiom.2025.106058_bib4","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41585-023-00764-9","article-title":"Obesity and prostate cancer - microenvironmental roles of adipose tissue","volume":"20","author":"Saha","year":"2023","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.ebiom.2025.106058_bib5","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejca.2022.04.005","article-title":"Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: a meta-analysis of AFFIRM, PREVAIL and PROSPER","volume":"170","author":"Joshua","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ebiom.2025.106058_bib6","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ejca.2022.03.042","article-title":"Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: secondary analysis of COU-AA-301 and COU-AA-302","volume":"170","author":"Wilson","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ebiom.2025.106058_bib7","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231152839","article-title":"Targeting lipid metabolism in metastatic prostate cancer","volume":"15","author":"Scheinberg","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"10.1016\/j.ebiom.2025.106058_bib8","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/s41391-021-00338-z","article-title":"Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer","volume":"24","author":"Lin","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"10","key":"10.1016\/j.ebiom.2025.106058_bib9","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/ijc.30903","article-title":"A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer","volume":"141","author":"Lin","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ebiom.2025.106058_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103625","article-title":"Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase","volume":"72","author":"Lin","year":"2021","journal-title":"eBioMedicine"},{"issue":"19","key":"10.1016\/j.ebiom.2025.106058_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194964","article-title":"Relationship between circulating lipids and cytokines in metastatic castration-resistant prostate cancer","volume":"13","author":"Lin","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ebiom.2025.106058_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-44157-9","article-title":"Untargeted lipidomics reveal association of elevated plasma C18 ceramide levels with reduced survival in metastatic castration-resistant prostate cancer patients","volume":"13","author":"Cattrini","year":"2023","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ebiom.2025.106058_bib13","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41391-023-00666-2","article-title":"PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer","volume":"27","author":"Scheinberg","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ebiom.2025.106058_bib14","series-title":"Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post-hoc analysis of the ENZAMET Phase 3 randomised trial (ANZUP 1304)","author":"Lin","year":"2025"},{"issue":"2","key":"10.1016\/j.ebiom.2025.106058_bib15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.yexcr.2015.02.025","article-title":"Revisiting the sphingolipid rheostat: evolving concepts in cancer therapy","volume":"333","author":"Newton","year":"2015","journal-title":"Exp Cell Res"},{"issue":"8","key":"10.1016\/j.ebiom.2025.106058_bib16","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s41419-023-06023-4","article-title":"Targeting SphK1\/2 by SKI-178 inhibits prostate cancer cell growth","volume":"14","author":"Jin","year":"2023","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/j.ebiom.2025.106058_bib17","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1038\/s41467-020-17645-z","article-title":"Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer","volume":"11","author":"Vykoukal","year":"2020","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.ebiom.2025.106058_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/biom10101393","article-title":"Identification of plasma glycosphingolipids as potential biomarkers for prostate cancer (PCa) status","volume":"10","author":"Snider","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.ebiom.2025.106058_bib19","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241307814","article-title":"Evolocumab in metastatic castration-resistant prostate cancer: study protocol for a single-arm, phase II trial, and initial experience with use of a validated lipid biomarker to direct therapy","volume":"16","author":"Mellor","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ebiom.2025.106058_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2019.105528","article-title":"Circulating sex steroid measurements of men by mass spectrometry are highly reproducible after prolonged frozen storage","volume":"197","author":"Handelsman","year":"2020","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"10","key":"10.1016\/j.ebiom.2025.106058_bib21","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1210\/en.2019-00340","article-title":"An accurate substitution method to minimize left censoring bias in serum steroid measurements","volume":"160","author":"Handelsman","year":"2019","journal-title":"Endocrinology"},{"issue":"10","key":"10.1016\/j.ebiom.2025.106058_bib22","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1194\/jlr.P035808","article-title":"Plasma lipid profiling in a large population-based cohort","volume":"54","author":"Weir","year":"2013","journal-title":"J Lipid Res"},{"issue":"1","key":"10.1016\/j.ebiom.2025.106058_bib23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.chembiol.2018.10.008","article-title":"High-Throughput plasma lipidomics: detailed mapping of the associations with cardiometabolic risk factors","volume":"26","author":"Huynh","year":"2019","journal-title":"Cell Chem Biol"},{"issue":"13","key":"10.1016\/j.ebiom.2025.106058_bib24","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.1021\/ac051632c","article-title":"Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics","volume":"78","author":"Dieterle","year":"2006","journal-title":"Anal Chem"},{"issue":"6","key":"10.1016\/j.ebiom.2025.106058_bib25","doi-asserted-by":"crossref","DOI":"10.1093\/gigascience\/giz061","article-title":"LION\/web: a web-based ontology enrichment tool for lipidomic data analysis","volume":"8","author":"Molenaar","year":"2019","journal-title":"Gigascience"},{"issue":"7","key":"10.1016\/j.ebiom.2025.106058_bib26","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat Methods"},{"issue":"1","key":"10.1016\/j.ebiom.2025.106058_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.ebiom.2025.106058_bib28","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70161","article-title":"Application of Human Plasma\/Serum to cell culture in vitro: a translational research approach to better define disease mechanisms","volume":"18","author":"Cela","year":"2025","journal-title":"Clin Transl Sci"},{"issue":"4","key":"10.1016\/j.ebiom.2025.106058_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.103042","article-title":"Lipidomic profiling of rat hepatic stellate cells during activation reveals a two-stage process accompanied by increased levels of lysosomal lipids","volume":"299","author":"Molenaar","year":"2023","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.ebiom.2025.106058_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/cells12050804","article-title":"Polyunsaturated fatty acids drive lipid peroxidation during Ferroptosis","volume":"12","author":"Mortensen","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.ebiom.2025.106058_bib31","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1186\/s12935-019-1014-8","article-title":"Roles of sphingosine-1-phosphate signaling in cancer","volume":"19","author":"Wang","year":"2019","journal-title":"Cancer Cell Int"},{"issue":"10","key":"10.1016\/j.ebiom.2025.106058_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15102732","article-title":"Targeting sphingosine 1-Phosphate metabolism as a therapeutic avenue for prostate cancer","volume":"15","author":"Mebarek","year":"2023","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.ebiom.2025.106058_bib33","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.bbrc.2017.03.084","article-title":"Modulation of the sphingolipid rheostat is involved in paclitaxel resistance of the human prostate cancer cell line PC3-PR","volume":"486","author":"Aoyama","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ebiom.2025.106058_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.plipres.2023.101241","article-title":"Pathophysiological roles and applications of glycosphingolipids in the diagnosis and treatment of cancer diseases","volume":"91","author":"Jin","year":"2023","journal-title":"Prog Lipid Res"},{"issue":"17","key":"10.1016\/j.ebiom.2025.106058_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174293","article-title":"Role of lipids and lipid metabolism in prostate cancer progression and the tumor's immune environment","volume":"14","author":"Siltari","year":"2022","journal-title":"Cancers"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235239642500502X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235239642500502X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T05:10:17Z","timestamp":1773897017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235239642500502X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":35,"alternative-id":["S235239642500502X"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.106058","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterising the effect of circulating sphingolipids on metastatic prostate cancer cells","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.106058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106058"}}